drugset
Drugs / Pegylated Interferon Lambda-1a
last change Feb 2017 re-read 3 minutes ago

Pegylated Interferon Lambda-1a

also known as Lambda

Protein / enzyme biologic

Developed for
chronic hepatitis C virus infection
Investigated by
Bristol-Myers Squibb

Trials 1

today NCT01866930 · Ph 3
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01866930 Jul 2013 → Aug 2015 chronic hepatitis C virus infection Bristol-Myers Squibb Terminated No outcome recorded Stop: Business

Press releases naming this drug 8 releases

DateIssuerRelease
2012-11-12 Bristol-Myers Squibb Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study bms.com ↗
2012-04-19 Bristol-Myers Squibb Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗
2011-04-02 Bristol-Myers Squibb Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients bms.com ↗
2010-10-31 Bristol-Myers Squibb Bristol-Myers Squibb Posts Data Update on PEG-Interferon Lambda, A Novel Interferon in Development for the Treatment of Hepatitis C bms.com ↗
2010-10-01 Bristol-Myers Squibb ZymoGenetics and Bristol-Myers Squibb to Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results at AASLD 2010 bms.com ↗
2009-10-31 Bristol-Myers Squibb Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C bms.com ↗
2009-10-01 Bristol-Myers Squibb Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009 bms.com ↗
2009-04-24 Bristol-Myers Squibb Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C bms.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Pegylated Interferon Lambda-1a ClinicalTrials.gov intervention name — accepted as the source's own label NCT01866930 ↗
Known as Lambda “pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV)” PMID 28282271 ↗ Feb 2017
Modality Protein / enzyme biologic “Biological: Pegylated Interferon Lambda-1a” NCT01866930 ↗
Route Subcutaneous “injection subcutaneously once weekly” NCT01866930 ↗